MorphoSys Announces Barclays PLC’s Voting Rights Shift
TipRanks (Fri, 3-May 11:27 AM ET)
MorphoSys AG Reports Shift in Major Holdings
TipRanks (Thu, 2-May 11:27 AM ET)
Barclays PLC Acquires 10% Stake in MorphoSys AG
TipRanks (Tue, 30-Apr 10:57 AM ET)
MorphoSys AG Navigates Takeover and Asset Sale
TipRanks (Tue, 30-Apr 9:59 AM ET)
MorphoSys AG Set for Novartis Acquisition
TipRanks (Mon, 29-Apr 5:00 PM ET)
Seeking Alpha News (Mon, 29-Apr 4:55 PM ET)
MorphoSys AG Reports First Quarter 2024 Financial Results
Business Wire (Mon, 29-Apr 4:01 PM ET)
Benzinga (Mon, 29-Apr 12:36 PM ET)
MorphoSys AG Announces Major Shareholder Update
TipRanks (Mon, 29-Apr 10:57 AM ET)
New safety risk for MorphoSys drug could complicate Novartis deal - STAT (update)
Seeking Alpha News (Mon, 29-Apr 7:06 AM ET)
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Morphosys Ag - American Depositary Shares trades on the NASDAQ stock market under the symbol MOR.
As of May 3, 2024, MOR stock price climbed to $17.89 with 454,978 million shares trading.
MOR has a beta of 0.26, meaning it tends to be less sensitive to market movements. MOR has a correlation of 0.00 to the broad based SPY ETF.
MOR has a market cap of $2.70 billion. This is considered a Mid Cap stock.
Last quarter Morphosys Ag - American Depositary Shares reported $30 million in Revenue and -$2.25 earnings per share. This fell short of revenue expectation by $-29 million and missed earnings estimates by -$1.90.
In the last 3 years, MOR stock traded as high as $24.19 and as low as $3.17.
The top ETF exchange traded funds that MOR belongs to (by Net Assets): IBB, APIE, AGNG, DFIC.
MOR has outperformed the market in the last year with a return of +242.7%, while the SPY ETF gained +26.1%. In the last 3 month period, MOR beat the market returning +61.6%, while SPY returned +3.7%. However, in the most recent 2 weeks MOR has underperformed the stock market by returning -0.9%, while SPY returned +2.4%.
MOR support price is $17.73 and resistance is $18.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MOR stock will trade within this expected range on the day.